Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis
2013
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI